Global Anemia Treatment Industry’s Striking 6.9% CAGR Leading to US$ 14.9 Billion by 2028 | FMI

The Global Anemia Treatment Industry achieved a remarkable milestone in 2022, exceeding a valuation of US$ 10.0 billion. Projections for the near future are nothing short of extraordinary, with market analysts forecasting a substantial expansion by 2028, envisioning a market worth US$ 14.9 billion. This anticipated growth is underpinned by robust sales performance, boasting an impressive Compound Annual Growth Rate (CAGR) of 6.9%.

In a recent report released by Future Market Insights, it is underscored that a significant portion of the demand for Anemia therapy can be attributed to cases arising from one or more chronic medical conditions.

The demand for Anemia treatment is chiefly driven by chronic kidney disease (CKD), one of the non-communicable chronic diseases contributing to the demographic shift in emerging regions. Additionally, the increasing popularity of combination therapy is poised to make a substantial impact on the Anemia treatment market. The growing utilization of antibiotics, metal chelating agents, erythropoietin-stimulating drugs, and vitamin and iron supplements in combination therapy is recognized as a key driver elevating the prospects of the Anemia treatment Industry in the years to come.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-8966

Vitamin Supplements Gain Significant Traction for Anemia Treatment

A surge in R&D investments is prominently improving the scope of anemia treatment. Moreover, a rising number of pipeline drugs and promising potential of biosimilars will contribute to the demand for anemia treatment. However, high price point associated with biologics continues to mask their superior treatment efficacy over conventional medications.

More than 75% of anemia treatment Industry revenue is accounted by medications, of which, ESAs (erythropoietin stimulating agents) remain bestselling. Blood transfusion also cited as an important type of anemia treatment, contributing to the market growth. However, the demand for former is poised for a robust double-digit yearly growth in 2021 and ahead.

Lucrative emergence of ESAs and soaring consumption of other biosimilar medications are likely to introduce new investment opportunities in anemia treatment market. Extensive availability, accessibility, and economic price point of biosimilar drugs is strongly backed by an increasing number of FDA approvals. This according to FMI will significantly contribute in improvement of CKD, thereby bolstering the revenue of the anemia treatment Industry. FDA recently issued an approval to a biosimilar drug by Pfizer for use in anemia treatment – Retacrit (epoetin alfa-epbx).

Over 55% of dietary supplements consumed as a part of anemia treatment are vitamin supplements. An increasing number of iron deficient patients will Unveil Click Here to Request Methodology!

Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-8966

reportedly result in rapid demand growth of iron supplements in years to come, posing strong competition to that of vitamin supplements in the anemia treatment market. Currently, almost 60% of the medications and dietary supplements for anemia treatment is available at institutional pharmacies. The report also points to a gradually expanding share of retail pharmacies in the near future.

North American patients raise just-under a third of the global demand for anemia treatment, whereas more than a third of the total demand is accounted collectively by East and South Asia. Europe is also cited as one of the key regional markets for anemia treatment providers.

Product-based Business Models Emerge as a Key Competitive Strategy

The consistent quest for therapeutically effective ESAs, dietary supplements, antibiotics, and other biologics to be used in anemia treatment continues to create attractive avenues in the R&D realm. Leading drug manufacturers are investing efforts in launching novel products and upgrading their existing consumable product portfolios. Amgen’s epoetin alpha has been a breakthrough product since its launch in the CKD treatment landscape and growing adoption continues to benefit the company.

Besides augmenting R&D investments, prominent players in the anemia treatment Industry are also focusing on strategic agreements and partnerships – further paving the way for development of anemia treatment drugs. The emergence of partnership-based models in the competitive landscape of anemia treatment market is likely to reshape R&D structure in the anemia treatment Industry. The report prompts at major investment opportunities arising in open collaboration strategies. A number of drug manufacturers are also opting for partnerships with regional distribution leaders to form effective product-based distribution channels, particularly targeting developing regional markets.

Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/8966

Global Anemia Treatment Industry by Category

By Treatment:

• Medications
• Dietary Supplements

By Disease:

• Normocytic anemia
• Microcytic anemia
• Macrocytic anemia

By Distribution Channel:

• Institutional Pharmacies
• Retail Pharmacies
• Mail Order Pharmacies

Key Companies Profiled:

1. Amgen Inc.
2. Hoffmann-La Roche Ltd.
3. Novartis AG
4. Pfizer Inc.
5. Janssen Pharmaceuticals, Inc.
6. Teva Pharmaceutical Industries Ltd.
7. AMAG Pharmaceuticals
8. Rockwell Medical
9. Akebia Therapeutics
10. Vifor Pharma Management Ltd.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Nandini Singh Sawlani

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube